Apnimed Inc (APMD) Stock Analysis
Verdict: AVOID
Dilution risk looms as cash burn of $77.8M leaves under 7 months runway to fund AD109 Phase 3 trials before commercialization.
Investment score: 35/100
Analysis as of
Is Apnimed Inc stock worth reviewing? AI model thesis
The AI model issues an AVOID rating on Apnimed Inc due to an unsustainable cash runway of under 7 months, steep technical downward momentum (-20.7% in 5 days), and high dilution risk despite positive clinical progress on AD109.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Apnimed Inc opportunities and risks
What speaks for APMD
- AD109 Phase 3 clinical progress targeting CPAP alternative market
What speaks against APMD
- Imminent dilutive capital raise due to 6.5-month cash runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SPTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.9% |
| ANRO | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.2% |
| ALMS | n/a | 113.4x | n/a | 88.2% | -5933.5% | -41.9% |
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.9% |
| LXRX | n/a | 18.7x | n/a | 98.9% | -147.4% | -10.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.2% |
Frequently asked questions about Apnimed Inc (APMD)
Is APMD stock a good investment?
The cached TradeMates AI model rates Apnimed Inc as AVOID with an investment score of 35/100. The AI model issues an AVOID rating on Apnimed Inc due to an unsustainable cash runway of under 7 months, steep technical downward momentum (-20.7% in 5 days), and high dilution risk despite positive clinical progress on AD109. This is algorithmic model output, not personal investment advice.
Is APMD stock a buy?
The TradeMates model verdict for APMD is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.